BiotechTube

CCX282-B + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Oct 1, 2007 → Jul 1, 2008

NCT ID
NCT00540657

About CCX282-B + Placebo

CCX282-B + Placebo is a phase 2 stage product being developed by Amgen for Celiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00540657. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00540657Phase 2Completed

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
DONQ52 + PlaceboChugai PharmaceuticalPhase 1
29
Placebo DONQ52 + DONQ52Chugai PharmaceuticalPhase 2
42
Placebo + RO5459072RochePhase 1
29
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
Rifaximin + PlaceboBausch HealthPre-clinical
20
LatiglutenaseAllergy TherapeuticsPhase 2
21
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26